Multiple myeloma (MM) is a B cell malignancy characterized by the accumulation of plasma cells and the production of immunoglobulins. Although important progress has been achieved in the treatment of this disease, curative treatments are still unavailable. Therefore it is necessary to develop new treatments in order to eradicate the disease. Usually, active treatments for hematological malignancies are based on combinations of several drugs (three or four) with different mechanisms of action. Although some novel drugs, such as bortezomib or the immunomodulatory compounds, have shown clear activity in MM, most patients relapse. This illustrates the need for investigating appropriate drug combinations in order to overcome drug resistance. The above facts clearly call for attempts to improve MM treatment by the use of combinations of drugs that act through different mechanisms. We have extended experience with two compounds, LBH589 and Aplidin, which target different routes with respect to conventional treatments. We intend o analyze whether Aplidin and LBH589 can potentiate the conventional anti-myeloma treatments.